Drugmakers are delaying new medicine launches in Europe due to U.S. pressure on lowering drug prices, impacting global market strategies and pricing dynamics. This affects developers by creating uncertainty in international market entry timelines and requiring careful navigation of regulatory environments. Additionally, Eli Lilly's $6.3 billion acquisition of Centessa Pharmaceuticals highlights ongoing consolidation in the narcolepsy treatment sector.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



